Lenvatinib proves its worth against HCC in the real-world settingFebruary 22, 2022Hepatocellular Carcinoma
GALAD performs modestly in detecting HCC in a phase 3 biomarker studyFebruary 22, 2022Hepatocellular Carcinoma
Resectable HCC: Neoadjuvant cemiplimab appears effective and safe in phase 2February 22, 2022Hepatocellular Carcinoma
Phase 2 validates the safety and efficacy of nivolumab with or without ipilimumab in resectable HCCFebruary 22, 2022Hepatocellular Carcinoma
Unfavorable intermediate-risk prostate cancer: EBRT plus BT improve survivalFebruary 15, 2022Prostate Cancer
Intermediate-/high-risk prostate cancer: Focal HIFU provides good controlFebruary 15, 2022Prostate Cancer
Prostate cancer: ACEi use during radiotherapy may protect against hematuriaFebruary 15, 2022Prostate Cancer
Obesity is linked to high-risk prostate cancer in multiethnic populationFebruary 15, 2022Prostate Cancer
Prostate cancer: Active surveillance may be appropriate in selected intermediate-risk patientsFebruary 15, 2022Prostate Cancer
Prostate cancer: Salvage radiotherapy after surgery extends long-term survivalFebruary 15, 2022Prostate Cancer
Metastatic CRPC: Autologous dendritic cell-based immunotherapy fails to extend survivalFebruary 15, 2022Prostate Cancer
